Cargando…

Sequential Cohort Design Applying Propensity Score Matching to Analyze the Comparative Effectiveness of Atorvastatin and Simvastatin in Preventing Cardiovascular Events

BACKGROUND: Sequential cohort design (SCD) applying matching for propensity scores (PS) in accrual periods has been proposed to mitigate bias caused by channeling when calendar time is a proxy for strong confounders. We studied the channeling of patients according to atorvastatin and simvastatin ini...

Descripción completa

Detalles Bibliográficos
Autores principales: Helin-Salmivaara, Arja, Lavikainen, Piia, Aarnio, Emma, Huupponen, Risto, Korhonen, Maarit Jaana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3948677/
https://www.ncbi.nlm.nih.gov/pubmed/24614626
http://dx.doi.org/10.1371/journal.pone.0090325
_version_ 1782306812781920256
author Helin-Salmivaara, Arja
Lavikainen, Piia
Aarnio, Emma
Huupponen, Risto
Korhonen, Maarit Jaana
author_facet Helin-Salmivaara, Arja
Lavikainen, Piia
Aarnio, Emma
Huupponen, Risto
Korhonen, Maarit Jaana
author_sort Helin-Salmivaara, Arja
collection PubMed
description BACKGROUND: Sequential cohort design (SCD) applying matching for propensity scores (PS) in accrual periods has been proposed to mitigate bias caused by channeling when calendar time is a proxy for strong confounders. We studied the channeling of patients according to atorvastatin and simvastatin initiation in Finland, starting from the market introduction of atorvastatin in 1998, and explored the SCD PS approach to analyzing the comparative effectiveness of atorvastatin versus simvastatin in the prevention of cardiovascular events (CVE). METHODS: Initiators of atorvastatin or simvastatin use in the 45–75-year age range in 1998–2006 were characterized by their propensity of receiving atorvastatin over simvastatin, as estimated for 17 six-month periods. Atorvastatin (10 mg) and simvastatin (20 mg) initiators were matched 1∶1 on the PS, as estimated for the whole cohort and within each period. Cox regression models were fitted conventionally, and also for the PS matched cohort and the periodically PS matched cohort, to estimate the hazard ratios (HR) for CVEs. FINDINGS: Atorvastatin (10 mg) was associated with a 11%–12% lower incidence of CVE in comparison with simvastatin (20 mg). The HR estimates were the same for a conventional Cox model (0.88, 95% confidence interval 0.85–0.91), for the analysis in which the PS was used to match across all periods and the Cox model was adjusted for strong confounders (0.89, 0.85–0.92), and for the analysis in which PS matching was applied within sequential periods (0.88, 0.84–0.92). The HR from a traditional PS matched analysis was 0.80 (0.77–0.83). CONCLUSIONS: The SCD PS approach produced effect estimates similar to those obtained in matching for PS within the whole cohort and adjusting the outcome model for strong confounders, but at the cost of efficiency. A traditional PS matched analysis without further adjustment in the outcome model produced estimates further away from unity.
format Online
Article
Text
id pubmed-3948677
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-39486772014-03-13 Sequential Cohort Design Applying Propensity Score Matching to Analyze the Comparative Effectiveness of Atorvastatin and Simvastatin in Preventing Cardiovascular Events Helin-Salmivaara, Arja Lavikainen, Piia Aarnio, Emma Huupponen, Risto Korhonen, Maarit Jaana PLoS One Research Article BACKGROUND: Sequential cohort design (SCD) applying matching for propensity scores (PS) in accrual periods has been proposed to mitigate bias caused by channeling when calendar time is a proxy for strong confounders. We studied the channeling of patients according to atorvastatin and simvastatin initiation in Finland, starting from the market introduction of atorvastatin in 1998, and explored the SCD PS approach to analyzing the comparative effectiveness of atorvastatin versus simvastatin in the prevention of cardiovascular events (CVE). METHODS: Initiators of atorvastatin or simvastatin use in the 45–75-year age range in 1998–2006 were characterized by their propensity of receiving atorvastatin over simvastatin, as estimated for 17 six-month periods. Atorvastatin (10 mg) and simvastatin (20 mg) initiators were matched 1∶1 on the PS, as estimated for the whole cohort and within each period. Cox regression models were fitted conventionally, and also for the PS matched cohort and the periodically PS matched cohort, to estimate the hazard ratios (HR) for CVEs. FINDINGS: Atorvastatin (10 mg) was associated with a 11%–12% lower incidence of CVE in comparison with simvastatin (20 mg). The HR estimates were the same for a conventional Cox model (0.88, 95% confidence interval 0.85–0.91), for the analysis in which the PS was used to match across all periods and the Cox model was adjusted for strong confounders (0.89, 0.85–0.92), and for the analysis in which PS matching was applied within sequential periods (0.88, 0.84–0.92). The HR from a traditional PS matched analysis was 0.80 (0.77–0.83). CONCLUSIONS: The SCD PS approach produced effect estimates similar to those obtained in matching for PS within the whole cohort and adjusting the outcome model for strong confounders, but at the cost of efficiency. A traditional PS matched analysis without further adjustment in the outcome model produced estimates further away from unity. Public Library of Science 2014-03-10 /pmc/articles/PMC3948677/ /pubmed/24614626 http://dx.doi.org/10.1371/journal.pone.0090325 Text en © 2014 Helin-Salmivaara et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Helin-Salmivaara, Arja
Lavikainen, Piia
Aarnio, Emma
Huupponen, Risto
Korhonen, Maarit Jaana
Sequential Cohort Design Applying Propensity Score Matching to Analyze the Comparative Effectiveness of Atorvastatin and Simvastatin in Preventing Cardiovascular Events
title Sequential Cohort Design Applying Propensity Score Matching to Analyze the Comparative Effectiveness of Atorvastatin and Simvastatin in Preventing Cardiovascular Events
title_full Sequential Cohort Design Applying Propensity Score Matching to Analyze the Comparative Effectiveness of Atorvastatin and Simvastatin in Preventing Cardiovascular Events
title_fullStr Sequential Cohort Design Applying Propensity Score Matching to Analyze the Comparative Effectiveness of Atorvastatin and Simvastatin in Preventing Cardiovascular Events
title_full_unstemmed Sequential Cohort Design Applying Propensity Score Matching to Analyze the Comparative Effectiveness of Atorvastatin and Simvastatin in Preventing Cardiovascular Events
title_short Sequential Cohort Design Applying Propensity Score Matching to Analyze the Comparative Effectiveness of Atorvastatin and Simvastatin in Preventing Cardiovascular Events
title_sort sequential cohort design applying propensity score matching to analyze the comparative effectiveness of atorvastatin and simvastatin in preventing cardiovascular events
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3948677/
https://www.ncbi.nlm.nih.gov/pubmed/24614626
http://dx.doi.org/10.1371/journal.pone.0090325
work_keys_str_mv AT helinsalmivaaraarja sequentialcohortdesignapplyingpropensityscorematchingtoanalyzethecomparativeeffectivenessofatorvastatinandsimvastatininpreventingcardiovascularevents
AT lavikainenpiia sequentialcohortdesignapplyingpropensityscorematchingtoanalyzethecomparativeeffectivenessofatorvastatinandsimvastatininpreventingcardiovascularevents
AT aarnioemma sequentialcohortdesignapplyingpropensityscorematchingtoanalyzethecomparativeeffectivenessofatorvastatinandsimvastatininpreventingcardiovascularevents
AT huupponenristo sequentialcohortdesignapplyingpropensityscorematchingtoanalyzethecomparativeeffectivenessofatorvastatinandsimvastatininpreventingcardiovascularevents
AT korhonenmaaritjaana sequentialcohortdesignapplyingpropensityscorematchingtoanalyzethecomparativeeffectivenessofatorvastatinandsimvastatininpreventingcardiovascularevents